HER2/neu-derived Peptides Are Shared Antigens among Human Non-Small Cell Lung Cancer and Ovarian Cancer

Ichiro Yoshino; Peter S. Goedegebuure; George E. Peoples; Akhil S. Parikh; Timothy J. Eberlein

HER2/neu-derived Peptides Are Shared Antigens among Human Non-Small Cell Lung Cancer and Ovarian Cancer

Ichiro Yoshino, Peter S. Goedegebuure, George E. Peoples, Akhil S. Parikh, Timothy J. Eberlein

Research output: Contribution to journal › Article › peer-review

Abstract

Previously, we have reported a correlation between the expression of HER2lneu and sensitivity to HLA-A2-restricted cytotoxic T-cells (CTL) in ovarian cancer. To investigate the role of HER2lneu in human non-small cell lung cancer (NSCLC), we established autologous tumor-specific CTL from tumor-infiltrating lymphocytes of HLA-A2+ HER2/ ne NSCLC patients. These CTL lines specifically recognized HLA-A2+ HER2/neU+ autologous and allogeneic NSCLC cell lines as well as HLA-A2+ HER2/neU+ heterologous ovarian cancer cell lines. Furthermore, these CTL recognized an overexpressed, HER2/neu-derived peptide. From these results, we conclude that HLA-A2 serves as a restriction element in NSCLC. More importantly, at least one HER2/neu-derived peptide is a tumor-associated antigen in NSCLC and ovarian cancer.

Original language	English
Pages (from-to)	3387-3390
Number of pages	4
Journal	Cancer research
Volume	54
Issue number	13
State	Published - Jul 1 1994

Cite this

@article{4376850cb6ad49a1882e175b71d4929a,

title = "HER2/neu-derived Peptides Are Shared Antigens among Human Non-Small Cell Lung Cancer and Ovarian Cancer",

abstract = "Previously, we have reported a correlation between the expression of HER2lneu and sensitivity to HLA-A2-restricted cytotoxic T-cells (CTL) in ovarian cancer. To investigate the role of HER2lneu in human non-small cell lung cancer (NSCLC), we established autologous tumor-specific CTL from tumor-infiltrating lymphocytes of HLA-A2+ HER2/ ne NSCLC patients. These CTL lines specifically recognized HLA-A2+ HER2/neU+ autologous and allogeneic NSCLC cell lines as well as HLA-A2+ HER2/neU+ heterologous ovarian cancer cell lines. Furthermore, these CTL recognized an overexpressed, HER2/neu-derived peptide. From these results, we conclude that HLA-A2 serves as a restriction element in NSCLC. More importantly, at least one HER2/neu-derived peptide is a tumor-associated antigen in NSCLC and ovarian cancer.",

author = "Ichiro Yoshino and Goedegebuure, {Peter S.} and Peoples, {George E.} and Parikh, {Akhil S.} and Eberlein, {Timothy J.}",

year = "1994",

month = jul,

day = "1",

language = "English",

volume = "54",

pages = "3387--3390",

journal = "Cancer research",

issn = "0008-5472",

number = "13",

}

TY - JOUR

T1 - HER2/neu-derived Peptides Are Shared Antigens among Human Non-Small Cell Lung Cancer and Ovarian Cancer

AU - Yoshino, Ichiro

AU - Goedegebuure, Peter S.

AU - Peoples, George E.

AU - Parikh, Akhil S.

AU - Eberlein, Timothy J.

PY - 1994/7/1

Y1 - 1994/7/1

N2 - Previously, we have reported a correlation between the expression of HER2lneu and sensitivity to HLA-A2-restricted cytotoxic T-cells (CTL) in ovarian cancer. To investigate the role of HER2lneu in human non-small cell lung cancer (NSCLC), we established autologous tumor-specific CTL from tumor-infiltrating lymphocytes of HLA-A2+ HER2/ ne NSCLC patients. These CTL lines specifically recognized HLA-A2+ HER2/neU+ autologous and allogeneic NSCLC cell lines as well as HLA-A2+ HER2/neU+ heterologous ovarian cancer cell lines. Furthermore, these CTL recognized an overexpressed, HER2/neu-derived peptide. From these results, we conclude that HLA-A2 serves as a restriction element in NSCLC. More importantly, at least one HER2/neu-derived peptide is a tumor-associated antigen in NSCLC and ovarian cancer.

AB - Previously, we have reported a correlation between the expression of HER2lneu and sensitivity to HLA-A2-restricted cytotoxic T-cells (CTL) in ovarian cancer. To investigate the role of HER2lneu in human non-small cell lung cancer (NSCLC), we established autologous tumor-specific CTL from tumor-infiltrating lymphocytes of HLA-A2+ HER2/ ne NSCLC patients. These CTL lines specifically recognized HLA-A2+ HER2/neU+ autologous and allogeneic NSCLC cell lines as well as HLA-A2+ HER2/neU+ heterologous ovarian cancer cell lines. Furthermore, these CTL recognized an overexpressed, HER2/neu-derived peptide. From these results, we conclude that HLA-A2 serves as a restriction element in NSCLC. More importantly, at least one HER2/neu-derived peptide is a tumor-associated antigen in NSCLC and ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=0028277739&partnerID=8YFLogxK

M3 - Article

C2 - 7912166

AN - SCOPUS:0028277739

SN - 0008-5472

VL - 54

SP - 3387

EP - 3390

JO - Cancer research

JF - Cancer research

IS - 13

ER -

HER2/neu-derived Peptides Are Shared Antigens among Human Non-Small Cell Lung Cancer and Ovarian Cancer

Abstract

Other files and links

Fingerprint

Cite this